CD248 and lymphoma: The clinical relevance of understanding how CD248 is regulated is highlighted by ongoing Phase 1 and 2 clinical trials in which the anti-CD248 antibody, MORAb-004, is being tested for efficacy in solid tumors and lymphomas (http://www.clinicaltrials.gov).